Identification of new genes downregulated in prostate cancer and investigation of their effects on prognosis

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 7, 2013, Pages 562-566

  Varisli, Lokman ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TROPOMYOSIN; CLUSTERIN; COLLAGEN TYPE 4; COLLAGEN TYPE 4 A6; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; TROPOMYOSIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; METASTASIS; PROSTATE CANCER;

ALDEHYDE OXIDASE; CLUSTERIN; COLLAGEN TYPE IV; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; RNA, MESSENGER; SURVIVAL RATE; TROPOMYOSIN;

EID: 84879952909     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0524     Document Type: Article

References (50)

1. Arredouani MS, Lu B, Bhasin M, et al. (2009) Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 15:5794-5802.
2. Assinder SJ, Au E, Dong Q, et al. (2010) A novel splice variant of the beta-tropomyosin (TPM2) gene in prostate cancer. Mol Carcinog 49:525-531.
3. Bettuzzi S, Davalli P, Astancolle S, et al. (2000) Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 60:28-34.
4. Chandran UR, Ma C, Dhir R, et al. (2007) Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7:64.
5. Chen AH, Tsau YW, Lin CH (2010) Novel methods to identify biologically relevant genes for leukemia and prostate cancer from gene expression profiles. BMC Genomics 11:274.
6. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. (2005) Proteomic analysis of chronic pancreatitis and pancreatic ad-enocarcinoma. Gastroenterology 129:1454-1463.
7. Dehan P, Waltregny D, Beschin A, et al. (1997) Loss of type IV collagen alpha 5 and alpha 6 chains in human invasive prostate carcinomas. Am J Pathol 151:1097-1104.
8. Garattini E, Mendel R, Romao MJ, et al. (2003) Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372:15-32.
9. Gevaert O, De Smet F, Timmerman D, et al. (2006) Predicting the prognosis of breast cancer by integrating clinical and micro-array data with Bayesian networks. Bioinformatics 22:e184-e190.
10. Grasso CS, Wu YM, Robinson DR, et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243.
11. Gregg JL, Brown KE, Mintz EM, et al. (2010) Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer 10:165.
12. Holzbeierlein J, Lal P, LaTulippe E, et al. (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227.
13. Ikeda K, Iyama K, Ishikawa N, et al. (2006) Loss of expression of type IV collagen alpha5 and alpha6 chains in colorectal cancer associated with the hypermethylation of their promoter region. Am J Pathol 168:856-865.
14. July LV, Akbari M, Zellweger T, et al. (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50:179-88.
15. Kim JH, Dhanasekaran SM, Prensner JR, et al. (2011) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 21:1028-1041.
16. Kim JW, Kim ST, Turner AR, et al. (2012) Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 7:e48455.
17. Kobayashi Y, Absher DM, Gulzar ZG, et al. (2011) DNA meth-ylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21:1017-1027.
18. Lapointe J, Li C, Higgins JP, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101:811-816.
19. LaTulippe E, Satagopan J, Smith A, et al. (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62:4499-4506.
20. Lin X, Tascilar M, Lee WH, et al. (2001) GSTP1 CpG island hy-permethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 159:1815-1826.
21. Liu P, Ramachandran S, Ali Seyed M, et al. (2006) Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66:4011-4019.
22. Luo JH, Yu YP, Cieply K, et al. (2002) Gene expression analysis of prostate cancers. Mol Carcinog 33:25-35.
23. Magee JA, Araki T, Patil S, et al. (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61:5692-5696.
24. Nakano S, Iyama K, Ogawa M, et al. (1999) Differential tissular expression and localization of type IV collagen alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors. Lab Invest 79:281-292.
25. Oster B, Thorsen K, Lamy P, et al. (2011) Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 129:2855-2866.
26. Pawlak G, Helfman DM (2001) Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 11:41-47.
27. Pins MR, Fiadjoe JE, Korley F, et al. (2004) Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis 7:243-248.
28. Porkka KP, Visakorpi T. (2001) Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array. J Pathol 193:73-79.
29. Rhodes DR, Yu JJ, Shanker K, et al. (2004) ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6:1-6.
30. Rizzi F, Bettuzzi S. (2010) The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 17:R1-R17.
31. Santourlidis S, Florl A, Ackermann R, et al. (1999) High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39:166-174.
32. Shiota M, Zardan A, Takeuchi A, et al. (2012) Clusterin mediates TGF-beta-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res 72:5261-5272.
33. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
34. Sigruener A, Buechler C, Orso E, et al. (2007) Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes. Horm Metab Res 39:781-789.
35. Singal R, van Wert J, Bashambu M (2001) Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res 61:4820-4826.
36. Singh D, Febbo PG, Ross K, et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
37. Stuart RO, Wachsman W, Berry CC, et al. (2004) In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A 101:615-620.
38. Tanaka K, Iyama K, Kitaoka M, et al. (1997) Differential expression of alpha 1(IV), alpha 2(IV), alpha 5(IV) and alpha 6(IV) collagen chains in the basement membrane of basal cell carcinoma. Histochem J 29:563-570.
39. Tanjore H, Kalluri R. (2006) The role of type IV collagen and basement membranes in cancer progression and metastasis. Am J Pathol 168:715-717.
40. Taylor BS, Schultz N, Hieronymus H, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22.
41. Tomlins SA, Mehra R, Rhodes DR, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39:41-51.
42. Varambally S, Yu J, Laxman B, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393-406.
43. Varisli L (2012) Meta-analysis of the expression of the mitosis-related gene Fam83D. Oncol Lett 4:1335-1340.
44. Wang L, Zhu JS, Song MQ, et al. (2006) Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray. World J Gastroenterol 12:6949-6954.
45. Welsh JB, Sapinoso LM, Su AI, et al. (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61:5974-5978.
46. Yagi K, Akagi K, Hayashi H, et al. (2010) Three DNA methyla-tion epigenotypes in human colorectal cancer. Clin Cancer Res 16:21-33.
47. Yu YP, Landsittel D, Jing L, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22:2790-2799.
48. Zhang H, Dong Y, Zhao H, et al. (2005) Microarray data mining for potential selenium targets in chemoprevention of prostate cancer. Cancer Genomics Proteomics 2:97-114.
49. Zhou M, Tokumaru Y, Sidransky D, et al. (2004) Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. J Urol 171:2195-2198.
50. Zigeuner R, Droschl N, Tauber V, et al. (2006) Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Urology 68:518-522.